^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-361175

    i
    Other names: BPI-361175
    Company:
    Betta Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    over2years
    A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    BPI-361175